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Derek R Brinster1,2* and Jay A Patel1,2Abstract
This manuscript presents a published record of the use and efficacy of the extracellular matrix CorMatrix and why it
may be superior to other materials used for aortic root enlargement. The potential benefits of an extracellular
matrix are the natural ingrowth and development of native arterial cells and structure.
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Aortic root enlargement (ARE) is a surgical procedure
used to widen the annulus of the aortic root to facilitate
aortic valve replacement (AVR). ARE is sometimes ne-
cessary to prevent patient-prosthesis mismatch, which
occurs when the area of the prosthesis is insufficient
relative to the size of the patient, and is associated with
higher rates mortality [1]. Both the orifice area of the
prosthesis and the resulting pressure gradient across the
aortic valve are important determinants to successful AVR.
Procedures used to enlarge the aortic root include the
Nicks’ Procedure which is the most common, Manougian
Technique, Seybold-Epting Technique, modified Bentall
Procedure, and aortoventriculoplasty. During AVR, an
effective means towards repair and augmentation of the
aortic root is necessary. Materials currently used for re-
construction are Dacron (cloth), polytetrafluroethlyene
(polymer), and bovine/patient derived pericardium [2].
Significant drawbacks to these materials include difficulty
in resorption and difficulty in promoting full functioning
of the reconstructed area [2]. An important alternative to
these methods is the CorMatrix ECM, an extracellular
matrix (ECM) derived from porcine small intestinal sub-
mucosa [3], which includes a matrix of structural proteins
normally found outside cells that provide tissue support.* Correspondence: derekbrinster@yahoo.com
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Case presentation
The following seven patients had an ARE procedure
performed between October 2011 and April 2013 due to
small annular size during AVR:
Case 1 patient. A 79-year-old female who presented
with significant shortness of breath, flash pulmonary
edema, severe aortic stenosis, ventricular hypertrophy,
and diastolic heart failure.
Case 2 patient. A 82-year-old male who presented with
shortness of breath, stenosis of the coronary artery
(LAD), severe atherosclerosis of the aortic valve, and a
thin aortic root.
Case 3 patient. A 40-year-old female who presented
with aortic valve murmur and worsening aortic stenosis
of her BAV.
Case 4 patient. A 75-year-old male who presented with
a history of heart failure, two surgeries involving a
coronary artery bypass graft, aortic stenosis, COPD,
hypertension, hyperlipidemia, atrial fibrillation, and
who had a biventricular ICD.
Case 5 patient. A 61-year-old African-American female
who presented with angina and dyspnea with exertion,
aortic stenosis, and a history of coronary artery disease
and stents.
Case 6 patient. A 44-year-old female who presented
with a congenital abnormality in her aortic valve, which
was accompanied with severe aortic stenosis.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with nonischemic cardiomyopathy, lowered ejection
fraction, and who had a biventricular ICD.
ARE was done by utilizing the Nick’s procedure to in-
crease the size of the aortic valve implantation. The annu-
lar size was increased by extending the aortotomy down
to the noncoronary sinus and traversing the annulus down
to the anterior leaflet of the mitral valve (Figure 1A,B).
The aortic valve prosthesis was then implanted into the
enlarged annulus, the patch was then used to augment the
aortic root to ensure no impingement on the biopros-
thetic, and the defect in the annulus was closed with the
CorMatrix ECM patch strut (Figure 1C,D).
All patients had successful aortic root enlargement.
The average size of the bioprosthetic valve was 23.3 ±
1.4 mm, and the average mean prosthetic gradient was
12.5 mmHg ±4.3 mmHg, the average peak prosthetic
gradient was 21.6 mmHg ±6.2 mmHg. There were no
postoperative reoperations for bleeding, no strokes, and
no operative mortality. Average length of stay was
10.3 days ±4.1 days. Routine postoperative transthoracic
echocardiograms performed revealed normal aortic root
appearance.
Conclusions
There is no definitive conclusion on the best material to
use for the reconstruction of cardiac tissue, but an excep-
tional material would possess tensile strength, hemostatic
abilities, calcification resistance, and inability to evoke an
immune response [4]. There is evidence that CorMatrix1
A B
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Figure 1 ARE procedure. (A) Incision in the aortic root (1). (B) Opening o
CorMatrix patch after AVR. (D) Sealed aortic root.possesses most of these characteristics as it is able to with-
stand 1200+ mmHg of pressure, and has not been demon-
strated to undergo calcification nor instigate an immune
response [5]. According to the successful outcomes and
rapid amelioration of the patients discussed, who dis-
played no apparent complications with regards to the im-
planted material, CorMatrix ECM may be better than
alternative materials in vivo. The most significant draw-
backs of the alternative materials include tearing, dislodge-
ment, erosion, and calcification [4]. Bovine pericardium
possesses additional problems including its cellularity
which does not promote growth and stimulates an im-
mune response [4]. Based on their compositions, Dacron
and polytetrafluoroethylene are unable to promote growth
of host tissue as well. CorMatrix ECM is a non-cellular ma-
terial consisting of only structural proteins, which effect-
ively mimics the natural environment of cells. CorMatrix
has been found to readily undergo reabsorption [3] and
promotes the growth of a new population of the host’s cells
[4]. For example, studies of CorMatrix ECM on augmenta-
tion cystoplasty showed significant degeneration of the
matrix at four weeks post operation, which was accompan-
ied with the proliferation of host ECM and vascularization
[3]. By 8 to 12 weeks after the surgery, the implanted
matrix was undetectable [3]. A patient who underwent
ARE with CorMatrix, displayed normal aortic morphology
30 weeks after the surgery [5]. CorMatrix offers the added
benefits of a lower probability of infection and ease of
implementation. Although the use of CorMatrix for
ARE procedures is promising post-operatively, further
studies involving a longer follow up period for the2
f the aortic root and exposure of the aortic valve (2). (C) Suturing of
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and allow for the assessment of longer term efficacy
of CorMatrix ECM.
Consent
Patients in this study have provided written consent to
the use of their medical data for academic endeavors,
such as submission of a case report to a medical journal,
through a consent form that was provided to the patient
and/or patient family prior to surgery. A copy of the
written consent is available for review by the Editor-in-
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